Comparative proteomics study on meglumine antimoniate sensitive and resistant leishmania tropica isolated from iranian anthroponotic cutaneous leishmaniasis patients;Étude protéomique comparative de souches Leishmania tropica sensibles ou résistantes á l'antimoniate de méglumine chez des patients iraniens atteints de leishmaniose cutanée anthroponotique

Eastern Mediterranean Health Journal

Volumn 18, Issue 2, 2012, Pages 165-171

  Hajjaran, H ^a   Azarian, B ^b   Mohebali, M ^a   Hadighi, R ^c   Assare, A ^a   Vaziri, B ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; MEGLUMINE ANTIMONATE; PROSTAGLANDIN F2 ALPHA; PROTEIN DISULFIDE ISOMERASE; RECEPTOR FOR ACTIVATED C KINASE 1; VESICULAR TRANSPORT PROTEIN;

ARTICLE; DOWN REGULATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; LEISHMANIA TROPICA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; SKIN LEISHMANIASIS; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 84857821847     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2012.18.2.165     Document Type: Article

References (31)

1. Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organization Technical Report Series, 1990, 793:1-158.
2. Desjeux P. Worldwide increasing risk factors for leishmaniasis. Medical Microbiology and Immunology, 2001, 190:77-79.
3. Mohebali M et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Tropica, 2007, 103:33-40.
4. Hajjaran H et al. Identification of Leishmania species isolated from human cutaneous Leishmaniasis, using RAPD-PCR. Iranian Journal of Public Health, 2004, 33:8-15.
5. Davies CR et al. Leishmaniasis: new approaches to disease control. BMJ (Clinical Research Ed.), 2003, 326:377-382.
6. Lira R et al. Evidence that the high incidence of treatment failures in Indian Kala-Azar is due to the emergence of antimony -resistant strains of Leishmania onovani. Journal of Infectious Diseases, 1999, 180:564-567.
7. Rojas R et al. NG. S. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. Journal of Infectious Diseases, 2006, 15:1375-1383.
8. Hadighi R et al. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Medicine, 2006, 3:e162.
9. Croft SL, Brun R. In vitro and in vivo models for the identification and evaluation of drugs active against Trypanosoma and Leishmania. In: Fairlamb AH, Ridley R, Vial H, eds. Drugs against parasitic diseases: R&D methodologies and issues. Geneva, World Health Organization, 2003:165-175.
10. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Advances in Parasitology, 2006, 61:223-274.
11. Berman JD, Chulay DJHD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. American Journal of Tropical Medicine and Hygiene, 1982, 31:459-465.
12. Berman JD. Gallalee JV ABG. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochemical Pharmacology, 1987, 36:197-201.
13. Callahan HL, Beverley SM. A member of the aldoketo reductase family confers methotrexate resistance in Leishmania. Journal of Biological Chemistry, 1992, 267:24165-24168.
14. Papadopoulou B, Roy G, Ouellette M. A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO Journal, 1992, 11:3601-3608.
15. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clinical Microbiology Reviews, 2006, 19:111-126.
16. Guimond C et al. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Research, 2003, 31:5886-5896.
17. Vergnes B et al. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Molecular and Cellular Proteomics, 2007, 6:88-101.
18. Hajjaran H et al. Protein profiling on meglumine antimoniate (glucantime (r)) sensitive and resistant L. tropica isolates by 2-dimentional gel electrophoresis: a preliminary study. Iranian Journal of Parasitology, 2009, 4:8-14.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 1976, 72:248-254.
20. Shevchenko A et al. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Analytical Chemistry, 1996, 68:850-858.
21. Papadopoulou B, Drummelsmith JOM. Proteomics to explore pathogenesis and drug resistance mechanisms in protozoan parasites. In: Hondermarck H. ed. Biomedical and pharmaceutical applications of proteomics. New York, Kluwer Academic, 2004.
22. Drummelsmith J et al. Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance. Journal of Biological Chemistry, 2004, 279:33273-33280.
23. El Fakhry Y, Ouellette M, Papadopoulou B. A proteomic approach to identify developmentally regulated proteins in Leishmania infantum. Proteomics, 2002, 2:1007-1017.
24. Acestor N et al. Establishing two dimensional gels for the analysis of Leishmania proteomes. Proteomics, 2002, 2:877-879.
25. Ahmed SB et al. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine, 2004, 22:1631-1639.
26. Kelly BL, Stetson DBaL, Richard M. Leishmania major LACK antigen is required for efficient vertebrate parasitization. Journal of Experimental Medicine, 2003, 198(11):1689-1698.
27. Ashutosh SS, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. Journal of Medical Microbiology, 2007, 56:143-153.
28. Leprohon P et al. Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryotic Cell, 2006, 5:1713-1725.
29. Zai A et al. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. Journal of Clinical Investigation, 1999, 103:393-399.
30. Kabututu Z et al. Prostaglandin production from arachidonic acid and evidence for a 9,11-endoperoxide prostaglandin H2 reductase in Leishmania. International Journal for Parasitology, 2002, 32:1693-1700.
31. Drummelsmith J et al. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Molecular and Cellular Proteomics, 2003, 2:146-155.